44 results on '"Gargot D"'
Search Results
2. Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials
- Author
-
Adenis, A., Alessio, A., Aouakli, A., Azzedine, A., Bedjaoui, A., Bidault, A., Blanchi, A., Botton, A., Cadier-Lagnes, A., Fatisse, A., Gagnaire, A., Gilbert, A., Gueye, A., Hollebecque, A., Lemaire, A., Mahamat, A., Marre, A., Patenotte, A., Rotenberg, A., Roussel, A., Thirot-Bidault, A., Votte, A., Weber, A., Zaanan, A., Dupont-Gossart, A.C., Villing, A.L., Queuniet, A.M., Coudert, B., Denis, B., Garcia, B., Lafforgue, B., Landi, B., Leduc, B., Linot, B., Paillot, B., Rhein, B., Winkfield, B., Barberis, C., Becht, C., Belletier, C., Berger, C., Bineau, C., Borel, C., Brezault, C., Buffet, C., Cornila, C., Couffon, C., De La Fouchardière, C., Giraud, C., Lecaille, C., Lepere, C., Lobry, C., Locher, C., Lombard-Bohas, C., Paoletti, C., Platini, C., Rebischung, C., Sarda, C., Vilain, C., Briac-Levaché, C., Auby, D., Baudet-Klepping, D., Bechade, D., Besson, D., Cleau, D., Festin, D., Gargot, D., Genet, D., Goldfain, D., Luet, D., Malka, D., Peré-Vergé, D., Pillon, D., Sevin-Robiche, D., Smith, D., Soubrane, D., Tougeron, D., Zylberait, D., Carola, E., Cuillerier, E., Dorval Danquechin, E., Echinard, E., Janssen, E., Maillard, E., Mitry, E., Norguet-Monnereau, E., Suc, E., Terrebonne, E., Zrihen, E., Pariente, E.A., Almaric, F., Audemar, F., Bonnetain, F., Desseigne, F., Dewaele, F., Di Fiore, F., Ghiringhelli, F., Husseini, F., Khemissa, F., Kikolski, F., Morvan, F., Petit-Laurent, F., Riot, F., Subtil, F., Zerouala-Boussaha, F., Caroli-Bosc, F.X., Boilleau-Jolimoy, G., Bordes, G., Cavaglione, G., Coulanjon, G., Deplanque, G., Gatineau-Saillant, G., Goujon, G., Medinger, G., Roquin, G., Brixi-Benmansour, H., Castanie, H., Lacroix, H., Maechel, H., Perrier, H., Salloum, H., Senellart, H., Baumgaertner, I., Cumin, I., Graber, I., Trouilloud, I., Boutin, J., Butel, J., Charneau, J., Cretin, J., Dauba, J., Deguiral, J., Egreteau, J., Ezenfis, J., Forestier, J., Goineau, J., Lacourt, J., Lafon, J., Martin, J., Meunier, J., Moreau, J., Provencal, J., Taieb, J., Thaury, J., Tuaillon, J., Vergniol, J., Villand, J., Vincent, J., Volet, J., Bachet, J.B., Barbare, J.C., Souquet, J.C., Grangé, J.D., Dor, J.F., Paitel, J.F., Jouve, J.L., Raoul, J.L., Cheula, J.M., Gornet, J.M., Sabate, J.M., Vantelon, J.M., Vaillant, J.N., Aucouturier, J.P., Barbieux, J.P., Herr, J.P., Lafargue, J.P., Lagasse, J.P., Latrive, J.P., Plachot, J.P., Ramain, J.P., Robin, J.P., Spano, J.P., Douillard, J.Y., Beerblock, K., Bouhier-Leporrier, K., Slimane Fawzi, K., Cany, L., Chone, L., Dahan, L., Gasnault, L., Rob, L., Stefani, L., Wander, L., Baconnier, M., Ben Abdelghani, M., Benchalal, M., Blasquez, M., Carreiro, M., Charbit, M., Combe, M., Duluc, M., Fayolle, M., Gignoux, M., Giovannini, M., Glikmanas, M., Mabro, M., Mignot, M., Mornet, M., Mousseau, M., Mozer, M., Pauwels, M., Pelletier, M., Porneuf, M., Ramdani, M., Schnee, M., Tissot, M., Zawadi, M., Clavero-Fabri, M.C., Gouttebel, M.C., Kaminsky, M.C., Galais, M.P., Abdelli, N., Barrière, N., Bouaria, N., Bouarioua, N., Delas, N., Gérardin, N., Hess-Laurens, N., Stremsdoerfer, N., Berthelet, O., Boulat, O., Capitain, O., Favre, O., Amoyal, P., Bergerault, P., Burtin, P., Cassan, P., Chatrenet, P., Chiappa, P., Claudé, P., Couzigou, P., Feydy, P., Follana, P., Geoffroy, P., Godeau, P., Hammel, P., Laplaige, P., Lehair, P., Martin, P., Novello, P., Pantioni, P., Pienkowski, P., Pouderoux, P., Prost, P., Ruszniewski, P., Souillac, P., Texereau, P., Thévenet, P., Haineaux, P.A., Benoit, R., Coriat, R., Lamy, R., Mackiewicz, R., Beorchia, S., Chaussade, S., Hiret, S., Jacquot, S., Lavau Denes, S., Montembault, S., Nahon, S., Nasca, S., Nguyen, S., Oddou-Lagraniere, S., Pesque-Penaud, S., Fratte, S.P., Chatellier, T., Mansourbakht, T., Morin, T., Walter, T., Boige, V., Bourgeois, V., Derias, V., Guérin-Meyer, V., Hautefeuille, V., Jestin Le Tallec, V., Lorgis, V., Quentin, V., Sebbagh, V., Veuillez, V., Adhoute, X., Coulaud, X., Becouarn, Y., Coscas, Y., Courouble, Y., Le Bricquir, Y., Molin, Y., Rinaldi, Y., Lam, Y.H., Ladhib, Z., Aparicio, Thomas, Ducreux, Michel, Faroux, Roger, Barbier, Emilie, Manfredi, Sylvain, Lecomte, Thierry, Etienne, Pierre-Luc, Bedenne, Laurent, Bennouna, Jaafar, Phelip, Jean-Marc, François, Eric, Michel, Pierre, Legoux, Jean-Louis, Gasmi, Mohamed, Breysacher, Gilles, Rougier, Philippe, De Gramont, Aimery, Lepage, Come, Bouché, Olivier, and Seitz, Jean-François
- Published
- 2018
- Full Text
- View/download PDF
3. Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001–02)
- Author
-
Aparicio, T., Lavau-Denes, S., Phelip, J.M., Maillard, E., Jouve, J.L., Gargot, D., Gasmi, M., Locher, C., Adhoute, X., Michel, P., Khemissa, F., Lecomte, T., Provençal, J., Breysacher, G., Legoux, J.L., Lepère, C., Charneau, J., Cretin, J., Chone, L., Azzedine, A., Bouché, O., Sobhani, I., Bedenne, L., Mitry, E., Amoyal, P., Auby, D., Bachet, J.B., Baconnier, M., Benoit, R., Berthelet, O., Bidault, A., Bineau, C., Bordes, G., Bouarioua, N., Boucher, E., Boulat, O., Cleau, D., Couzigou, P., Cuillerier, E., Cumin, I., Denis, B., Di Fiore, F., Derias, V., Ezenfis, J., Faroux, R., Gagnaire, A., Gatineau-Sailliant, G., Garcia, B., Genet, D., Gueye, A., Hammel, P., Lagasse, J.P., Landi, B., Lepage, C., Lobry, C., Lombard-Bohas, C., Mabro, M., Mackiewicz, R., Martin, J., Moncoucy, X., Morvan, F., Mozer, M., Pauwels, M., Petit-Laurent, F., Pouderoux, P., Prost, P., Queuniet, A.M., Ramdani, M., Rebischung, C., Rougier, P., Schnee, M., Seitz, J.F., Stefani, L., Taïeb, J., Terrebonne, E., Texereau, P., Thaury, J., Tougeron, D., Weber, A., Ricard, F., Bonnetain, F., Masskouri, F., Choine, C., Guiliani, F., Le Pessec, G., Fattouh, H., Le Provost, N., Girault, C., and Schneider, M.
- Published
- 2016
- Full Text
- View/download PDF
4. LBA21 Neoadjuvant mFOLFIRINOX and preoperative chemoradiation (CRT) versus preoperative CRT in patients with T3-4 rectal cancer: Surgical and quality of life results of PRODIGE 23 phase III trial
- Author
-
Borg, C., Rullier, E., Marchal, F., Etienne, P-L., Rio, E., Francois, E., Mesgouez-Nebout, N., Vendrely, V., Artignan, X., Bouche, O., Gargot, D., Boige, V., Bonichon-Lamichhane, N., Louvet, C., Morand, C., de la Fouchardiere, C., Juzyna, B., Mollevi, C., Castan, F., and Conroy, T.
- Published
- 2020
- Full Text
- View/download PDF
5. Antibodies to hepatitis C virus in patients with positive HBsAg
- Author
-
Gargot, D., Ducreux, M., Dussaix, E., Pelletier, G., Briantais, M. J., Yvart, J., and Buffet, C.
- Published
- 1990
- Full Text
- View/download PDF
6. 3030 POSTER Randomized strategical trial of chemotherapy in metastatic colorectal cancer (FFCD 2000–05): preliminary results
- Author
-
Ducreux, M., Castaing, M., Etienne, P.L., Texereau, P., Auby, D., Bedenne, L., Rougier, P., Gargot, D., Gasmi, M., and Bouché, O.
- Published
- 2007
- Full Text
- View/download PDF
7. Efficacy of pegylated interferon alpha-2B in combination with ribavirin in patients with chronic hepatitis C non-responders to a previous treatment
- Author
-
Chousterman, M., Auray-Cartier, V., Hagege, H., Arpurt, J.P., Cassan, P., Denis, J., Gargot, D., Nalet, B., Nouel, O., Pariente, A., and Wartelle-Bladou, C.
- Published
- 2003
- Full Text
- View/download PDF
8. Anaphylactic Reaction to Oxaliplatin: A Case Report.
- Author
-
Larzillière, I., Brandissou, S., Breton, P., Lingoungou, A., Gargot, D., Ramain, J. P., Harnois, C., and Johnson, David
- Subjects
LETTERS to the editor ,COLON cancer - Abstract
Presents a letter to the editor about the side effects of oxaliplatin in a patient with metastatic colorectal cancer.
- Published
- 1999
- Full Text
- View/download PDF
9. Effects of intravenous administration of dexamethasone in the treatment of alcohol withdrawal syndrome.
- Author
-
Davido, Alain, Cadranel, Jean-François, Levy, Albert, Benhamou, Yves, Gargot, Dany, Leplat, Patrick, Valla, Dominique, Opolon, Pierre, Davido, A, Cadranel, J F, Levy, A, Benhamou, Y, Gargot, D, Leplat, P, Valla, D, and Opolon, P
- Published
- 1994
- Full Text
- View/download PDF
10. CREST syndrome: nodular regenerative hyperplasia of the liver and primary biliary cirrhosis an overlap syndrome?
- Author
-
Cadranel, J F, Grippon, P, Gargot, D, and Opolon, P
- Published
- 1990
11. A Case of Association between Hepatocellular Carcinoma and Porphyria Variegata.
- Author
-
Germanaud, J., Luthier, F., Causse, X., Kerdraon, R., Grossetti, D., Gargot, D., and Nordmann, Y.
- Published
- 1994
- Full Text
- View/download PDF
12. Sarcoïdose et réaction sarcoïdosique associées à la maladie de Hodgkin
- Author
-
Gargot, D., Algayres, J.P., Brunet, C., L'Her, P., Valmary, J.P., Maurel, C., and Daly, J.P.
- Published
- 1990
- Full Text
- View/download PDF
13. Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial.
- Author
-
Ducreux M, Malka D, Mendiboure J, Etienne PL, Texereau P, Auby D, Rougier P, Gasmi M, Castaing M, Abbas M, Michel P, Gargot D, Azzedine A, Lombard-Bohas C, Geoffroy P, Denis B, Pignon JP, Bedenne L, Bouché O, and Fédération Francophone de Cancérologie Digestive (FFCD) 2000-05 Collaborative Group
- Abstract
Background: The optimum use of cytotoxic drugs for advanced colorectal cancer has not been defined. Our aim was to investigate whether combination treatment is better than the sequential administration of the same drugs in patients with advanced colorectal cancer.Methods: In this open-label, randomised, phase 3 trial, we randomly assigned patients (1:1 ratio) with advanced, measurable, non-resectable colorectal cancer and WHO performance status 0-2 to receive either first-line treatment with bolus (400 mg/m(2)) and infusional (2400 mg/m(2)) fluorouracil plus leucovorin (400 mg/m(2)) (simplified LV5FU2 regimen), second-line LV5FU2 plus oxaliplatin (100 mg/m(2)) (FOLFOX6), and third-line LV5FU2 plus irinotecan (180 mg/m(2)) (FOLFIRI) or first-line FOLFOX6 and second-line FOLFIRI. Chemotherapy was administered every 2 weeks. Randomisation was done centrally using minimisation (minimisation factors were WHO performance status, previous adjuvant chemotherapy, number of disease sites, and centre). The primary endpoint was progression-free survival after two lines of treatment. Analyses were by intention-to-treat. This trial is registered at ClinicalTrials.gov, NCT00126256.Findings: 205 patients were randomly assigned to the sequential group and 205 to the combination group. 161 (79%) patients in the sequential group and 161 (79%) in the combination group died during the study. Median progression-free survival after two lines was 10·5 months (95% CI 9·6-11·5) in the sequential group and 10·3 months (9·0-11·9) in the combination group (hazard ratio 0·95, 95% CI 0·77-1·16; p=0·61). All six deaths caused by toxic effects of treatment occurred in the combination group. During first-line chemotherapy, significantly fewer severe (grade 3-4) haematological adverse events (12 events in 203 patients in sequential group vs 83 events in 203 patients in combination group; p<0·0001) and non-haematological adverse events (26 events vs 186 events; p<0·0001) occurred in the sequential group than in the combination group.Interpretation: Upfront combination chemotherapy is more toxic and is not more effective than the sequential use of the same cytotoxic drugs in patients with advanced, non-resectable colorectal cancer.Funding: Sanofi-Aventis France. [ABSTRACT FROM AUTHOR]- Published
- 2011
- Full Text
- View/download PDF
14. Ascitic dialytic ultrafiltration associated with peritoneal reinfusion of the concentrate comparison with large paracenthesis
- Author
-
Cadranel, J.F., Gargot, D., Grippon, P., Valla, D., and Opolon, P.
- Published
- 1990
- Full Text
- View/download PDF
15. Simultaneous dialytic ultrafiltration and intraperitoneal reinfusion in cirrhotic patients with intractable ascites: Preliminary results of a comparative study versos large paracentesis
- Author
-
Cadranel, Jean François, Grippon, P., Gargot, D., Lunel, Françoise, Bernard, B., Valla, Dominique, and Opolon, René
- Published
- 1992
- Full Text
- View/download PDF
16. Comparison of short course radiotherapy with chemoradiotherapy for locally advanced rectal cancers in the elderly: A multicentre, randomised, non-blinded, phase 3 trial.
- Author
-
François E, De Bari B, Ronchin P, Nouhaud E, Martel-Lafay I, Artru P, Clavere P, Vendrely V, Boige V, Gargot D, Lemanski C, De Sousa Carvalho N, Gal J, Pernot M, and Magné N
- Subjects
- Humans, Aged, Activities of Daily Living, Neoplasm Staging, Chemoradiotherapy adverse effects, Chemoradiotherapy methods, Capecitabine, Neoadjuvant Therapy adverse effects, Fluorouracil, Antineoplastic Combined Chemotherapy Protocols, Treatment Outcome, Rectum pathology, Rectal Neoplasms pathology
- Abstract
Background: There is no specific guideline for the treatment of locally advanced rectal cancers in the elderly. Here we compared R0 resection rate and degradation of autonomy based on the instrumental activities of daily living score between neoadjuvant, short course radiotherapy and chemoradiotherapy in this specific population., Patients and Methods: Patients ≥75 years with resectable T3-T4 rectal adenocarcinoma within 12 cm of the anal verge or T2 of the very low rectum were randomised between short course radiotherapy (5 × 5 Gy in one week) and chemoradiotherapy (50 Gy, 2 Gy/f, 5 weeks with capecitabine: 800 mg/m
2 twice daily, 5 days per week), with delayed surgery 7 ± 1 weeks for the two arms., Results: One hundred and three eligible patients were enrolled between January 2016 and December 2019 when the trial was closed due to poor accrual. The R0 resection rate (first co-primary objective) was 84.3%; confidence interval 95% [73.26-94.18] in the short course group and 88%; confidence interval 95% [77.77-96.60] in the chemoradiotherapy group (non-inferiority p = 0.28). The deterioration of the instrumental activities of daily living score was not different during the pre-operative phase, it was significantly more deteriorated in the chemoradiotherapy group at 3 months post-operative (44.8% versus 14.8%; p = 0.032) but was not different at 12 months post-operative (second co-primary objective). During pre-operative phase, 9.8% of patients in short course group and 22% of patients in chemoradiotherapy group presented a serious adverse event, but we observed no difference during the post-operative phase between the two groups., Conclusion: Although the main objectives of the study were not achieved, the short course radiotherapy followed by delayed surgery could represent a preferred treatment option in patients ≥75 years with locally advanced rectal cancer; a new study must be performed to confirm the improvement in overall and specific survival results., Competing Interests: Conflict of interest statement The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2022 Elsevier Ltd. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
17. The PRSS3P2 and TRY7 deletion copy number variant modifies risk for chronic pancreatitis.
- Author
-
Masson E, Ewers M, Paliwal S, Kume K, Scotet V, Cooper DN, Rebours V, Buscail L, Rouault K, Abrantes A, Aguilera Munoz L, Albouys J, Alric L, Amiot X, Archambeaud I, Audiau S, Bastide L, Baudon J, Bellaiche G, Bellon S, Bertrand V, Bideau K, Billiemaz K, Billioud C, Bonnefoy S, Borderon C, Bournet B, Breton E, Brugel M, Buscail L, Cadiot G, Camus M, Carpentier-Pourquier M, Chamouard P, Chaput U, Chen JM, Cholet F, Ciocan DM, Clavel C, Coffin B, Coimet-Berger L, Cosconea S, Creveaux I, Culetto A, Daboussi O, De Mestier L, Degand T, D'engremont C, Denis B, Dermine S, Desgrippes, Drouet D'Aubigny A, Enaud R, Fabre A, Férec C, Gargot D, Gelsi E, Gentilcore E, Gincul R, Ginglinger-Favre E, Giovannini M, Gomercic C, Gondran H, Grainville T, Grandval P, Grasset D, Grimaldi S, Grimbert S, Hagege H, Heissat S, Hentic O, Herber-Mayne A, Hervouet M, Hoibian S, Jacques J, Jais B, Kaassis M, Koch S, Lacaze E, Lacroute J, Lamireau T, Laurent L, Le Guillou X, Le Rhun M, Leblanc S, Levy P, Lievre A, Lorenzo D, Maire F, Marcel K, Masson E, Mauillon J, Morgant S, Moussata D, Muller N, Nambot S, Napoleon B, Olivier A, Pagenault M, Pelletier AL, Pennec O, Pinard F, Pioche M, Prost B, Queneherve L, Rebours V, Reboux N, Rekik S, Riachi G, Rohmer B, Roquelaure B, Rosa Hezode I, Rostain F, Saurin JC, Servais L, Stan-Iuga R, Subtil C, Tanneche J, Texier C, Thomassin L, Tougeron D, Vuitton L, Wallenhorst T, Wangerme M, Zanaldi H, Zerbib F, Bhaskar S, Kikuta K, Rao GV, Hamada S, Reddy DN, Masamune A, Chandak GR, Witt H, Férec C, and Chen JM
- Subjects
- Humans, Alleles, DNA Copy Number Variations genetics, Genetic Predisposition to Disease, Genotype, Mutation, Trypsin genetics, Pancreatitis, Chronic genetics, Trypsinogen genetics
- Abstract
Background: PRSS1 and PRSS2 constitute the only functional copies of a tandemly-arranged five-trypsinogen-gene cluster (i.e., PRSS1, PRSS3P1, PRSS3P2, TRY7 and PRSS2) on chromosome 7q35. Variants in PRSS1 and PRSS2, including missense and copy number variants (CNVs), have been reported to predispose to or protect against chronic pancreatitis (CP). We wondered whether a common trypsinogen pseudogene deletion CNV (that removes two of the three trypsinogen pseudogenes, PRSS3P2 and TRY7) might be associated with CP causation/predisposition., Methods: We analyzed the common PRSS3P2 and TRY7 deletion CNV in a total of 1536 CP patients and 3506 controls from France, Germany, India and Japan by means of quantitative fluorescent multiplex polymerase chain reaction., Results: We demonstrated that the deletion CNV variant was associated with a protective effect against CP in the French, German and Japanese cohorts whilst a trend toward the same association was noted in the Indian cohort. Meta-analysis under a dominant model yielded a pooled odds ratio (OR) of 0.68 (95% confidence interval (CI) 0.52-0.89; p = 0.005) whereas an allele-based meta-analysis yielded a pooled OR of 0.84 (95% CI 0.77-0.92; p = 0.0001). This protective effect is explicable by reference to the recent finding that the still functional PRSS3P2/TRY7 pseudogene enhancers upregulate pancreatic PRSS2 expression., Conclusions: The common PRSS3P2 and TRY7 deletion CNV was associated with a reduced risk for CP. This finding provides additional support for the emerging view that dysregulated PRSS2 expression represents a discrete mechanism underlying CP predisposition or protection., Competing Interests: Declaration of competing interest The authors are unaware of any conflict of interest., (Copyright © 2022 IAP and EPC. Published by Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
18. How are patients' preferences for anti-TNF influenced by quality of life? A discrete choice experiment in Crohn's disease patients.
- Author
-
Brunet-Houdard S, Monmousseau F, Berthon G, Des Garets V, Laharie D, Picon L, Fotsing G, Gargot D, Charpentier C, Buisson A, Trang-Poisson C, Dib N, Rusch E, and Aubourg A
- Subjects
- Humans, Patient Preference, Quality of Life, Tumor Necrosis Factor Inhibitors, Surveys and Questionnaires, Choice Behavior, Crohn Disease drug therapy
- Abstract
Background and Objective: Anti-TNFs have been shown to significantly improve the health-related quality of life (HRQoL) in Crohn's disease (CD) patients. The purpose of this study was to investigate to what extend the patients' preferences for these intravenous (IV) and subcutaneous (SC) treatments differ based on respondents' quality of life. An online discrete choice experiment (DCE) was conducted to understand patient trade-offs in treatment choice., Methods: Fifty-seven Crohn's disease anti-TNF naïve patients were asked to choose between two different scenarios, considering the following attributes: mode of administration (MODE), total availability for injection (TIME), speed of onset (DELAY), risk of anti-TNF administration despite a contraindication (RISK) and total monthly out-of-pocket expenses (COST). At the same time, patients completed the IBDQ-32 questionnaire. Conditional logit models without and with interaction terms were estimated to evaluate attribute weights., Results: Patients preferred to self-administer SC anti-TNF rather than have a primary care nurse do it, whereas the preference for IV route was negative. After adding interaction terms however, the IV route became preferred for patients with impaired HRQoL, this preference having decreased as HRQoL increased. Surprisingly, patients with impaired HRQoL were less willing to spend more time on treatment, and this effect diminished as HRQoL (overall and in each dimension) became higher., Conclusions: HRQoL level changed patients' preferences for the anti-TNF treatment. The results suggest the need to optimise the management of IV infusions in the hospital and reinforce the importance of patient-reported outcome measures (PROMS) as a common practice to improve shared medical decision making.
- Published
- 2022
- Full Text
- View/download PDF
19. Predictors of each quality of life dimension in Crohn's disease patients initiating an anti-TNF treatment: differentiated effects of patient-, disease-, and treatment-related characteristics.
- Author
-
Monmousseau F, Mulot L, Rusch E, Picon L, Laharie D, Fotsing G, Gargot D, Charpentier C, Buisson A, Trang-Poisson C, Dib N, DES Garets V, Brunet-Houdard S, and Aubourg A
- Subjects
- Child, Humans, Prospective Studies, Quality of Life, Tumor Necrosis Factor Inhibitors, Crohn Disease drug therapy, Crohn Disease psychology
- Abstract
Background and Aims: In Crohn's disease (CD), a composite therapeutic target was recently recommended, including both objective measurement (endoscopic remission) and Patient-Reported Outcomes (resolution of abdominal pain and normalization of bowel function). All dimensions of health-related quality of life (HRQoL) are impacted: not only bowel symptoms but also systemic symptoms, emotional wellbeing and social function. Thus, understanding the predictors of each HRQoL dimension would improve patient management. However, analysis of these factors has only been found in a few publications, with some limitations. Therefore, this study aimed to explore the evolution of the HRQoL of CD patients during six months after initiation of anti-TNF and to identify its predictors., Methods: We analyzed data of 56 patients included in a multicenter prospective cohort study (COQC-PIT). HRQoL measures (using IBDQ-32) and data related to patient, disease and treatment characteristics were collected every two months. Generalized estimating equations were used., Results: Overall HRQoL was significantly improved 2 months after anti-TNF initiation, and then stagnated. Patient, disease, and treatment characteristics have differentiated impacts on the overall score and on each dimension of quality of life. Subcutaneous anti-TNF had no significant effect on overall HRQoL, improving only emotional function and bowel symptoms. Concomitant use of corticosteroids and/or immunomodulators impaired almost all dimensions. Having children or working altered bowel symptoms. Disease duration and active smoking negatively impact emotional function and systemic symptoms., Conclusions: Each HRQoL dimension, not only bowel symptoms, and their influencing factors should therefore be considered in medical decision-making, especially in months following the initiation of a new treatment such as anti-TNF.
- Published
- 2022
- Full Text
- View/download PDF
20. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.
- Author
-
Conroy T, Bosset JF, Etienne PL, Rio E, François É, Mesgouez-Nebout N, Vendrely V, Artignan X, Bouché O, Gargot D, Boige V, Bonichon-Lamichhane N, Louvet C, Morand C, de la Fouchardière C, Lamfichekh N, Juzyna B, Jouffroy-Zeller C, Rullier E, Marchal F, Gourgou S, Castan F, and Borg C
- Subjects
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Female, Fluorouracil adverse effects, Fluorouracil therapeutic use, Humans, Irinotecan adverse effects, Irinotecan therapeutic use, Leucovorin adverse effects, Leucovorin therapeutic use, Male, Middle Aged, Neoadjuvant Therapy, Oxaliplatin adverse effects, Oxaliplatin therapeutic use, Quality of Life, Rectal Neoplasms mortality, Rectal Neoplasms psychology, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Chemoradiotherapy, Rectal Neoplasms therapy
- Abstract
Background: Treatment of locally advanced rectal cancer with chemoradiotherapy, surgery, and adjuvant chemotherapy controls local disease, but distant metastases remain common. We aimed to assess whether administering neoadjuvant chemotherapy before preoperative chemoradiotherapy could reduce the risk of distant recurrences., Methods: We did a phase 3, open-label, multicentre, randomised trial at 35 hospitals in France. Eligible patients were adults aged 18-75 years and had newly diagnosed, biopsy-proven, rectal adenocarcinoma staged cT3 or cT4 M0, with a WHO performance status of 0-1. Patients were randomly assigned (1:1) to either the neoadjuvant chemotherapy group or standard-of-care group, using an independent web-based system by minimisation method stratified by centre, extramural extension of the tumour into perirectal fat according to MRI, tumour location, and stage. Investigators and participants were not masked to treatment allocation. The neoadjuvant chemotherapy group received neoadjuvant chemotherapy with FOLFIRINOX (oxaliplatin 85 mg/m
2 , irinotecan 180 mg/m2 , leucovorin 400 mg/m2 , and fluorouracil 2400 mg/m2 intravenously every 14 days for 6 cycles), chemoradiotherapy (50 Gy during 5 weeks and 800 mg/m2 concurrent oral capecitabine twice daily for 5 days per week), total mesorectal excision, and adjuvant chemotherapy (3 months of modified FOLFOX6 [intravenous oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 , followed by intravenous 400 mg/m2 fluorouracil bolus and then continuous infusion at a dose of 2400 mg/m2 over 46 h every 14 days for six cycles] or capecitabine [1250 mg/m2 orally twice daily on days 1-14 every 21 days]). The standard-of-care group received chemoradiotherapy, total mesorectal excision, and adjuvant chemotherapy (for 6 months). The primary endpoint was disease-free survival assessed in the intention-to-treat population at 3 years. Safety analyses were done on treated patients. This trial was registered with EudraCT (2011-004406-25) and ClinicalTrials.gov (NCT01804790) and is now complete., Findings: Between June 5, 2012, and June 26, 2017, 461 patients were randomly assigned to either the neoadjuvant chemotherapy group (n=231) or the standard-of-care group (n=230). At a median follow-up of 46·5 months (IQR 35·4-61·6), 3-year disease-free survival rates were 76% (95% CI 69-81) in the neoadjuvant chemotherapy group and 69% (62-74) in the standard-of-care group (stratified hazard ratio 0·69, 95% CI 0·49-0·97; p=0·034). During neoadjuvant chemotherapy, the most common grade 3-4 adverse events were neutropenia (38 [17%] of 225 patients) and diarrhoea (25 [11%] of 226). During chemoradiotherapy, the most common grade 3-4 adverse event was lymphopenia (59 [28%] of 212 in the neoadjuvant chemotherapy group vs 67 [30%] of 226 patients in the standard-of-care group). During adjuvant chemotherapy, the most common grade 3-4 adverse events were lymphopenia (18 [11%] of 161 in the neoadjuvant chemotherapy group vs 42 [27%] of 155 in the standard-of-care group), neutropenia (nine [6%] of 161 vs 28 [18%] of 155), and peripheral sensory neuropathy (19 [12%] of 162 vs 32 [21%] of 155). Serious adverse events occurred in 63 (27%) of 231 participants in the neoadjuvant chemotherapy group and 50 (22%) of 230 patients in the standard-of-care group (p=0·167), during the whole treatment period. During adjuvant therapy, serious adverse events occurred in 18 (11%) of 163 participants in the neoadjuvant chemotherapy group and 36 (23%) of 158 patients in the standard-of-care group (p=0·0049). Treatment-related deaths occurred in one (<1%) of 226 patients in the neoadjuvant chemotherapy group (sudden death) and two (1%) of 227 patients in the standard-of-care group (one sudden death and one myocardial infarction)., Interpretation: Intensification of chemotherapy using FOLFIRINOX before preoperative chemoradiotherapy significantly improved outcomes compared with preoperative chemoradiotherapy in patients with cT3 or cT4 M0 rectal cancer. The significantly improved disease-free survival in the neoadjuvant chemotherapy group and the decreased neurotoxicity indicates that the perioperative approach is more efficient and better tolerated than adjuvant chemotherapy. Therefore, the PRODIGE 23 results might change clinical practice., Funding: Institut National du Cancer, Ligue Nationale Contre le Cancer, and R&D Unicancer., Competing Interests: Declaration of interests P-LE reports grants and non-financial support from Bristol Myers Squibb; and non-financial support from Amgen, Ipsen, Novartis, Roche, Sanofi, and Servier, outside the submitted work. OB reports personal fees from Amgen, Bayer, Bristol Myers Squibb, Grunenthal, Merck, Pierre Fabre, Roche, and Servier, outside the submitted work, and has been invited to congresses by Roche and Servier. VB reports grants from Merck Serono; personal fees from Merck Serono, Bayer, Bristol Myers Squibb, Sanofi, Eisai, Ipsen, Merck Sharpe and Dohme, and Prestizia; and non-financial support from Merck Serono, Bayer, Sanofi, and Roche, outside the submitted work. CL reports personal fees from Amgen, Celgene, Halozyme, Merck Sharpe and Dohme, and Roche, outside the submitted work. CdlF reports personal fees from Eisai, Amgen, Bayer, Pierre Fabre Oncologie, Roche, and Servier; and non-financial support from Amgen, Bayer, Pierre Fabre Oncologie, Roche, Servier, and Bristol Myers Squibb, outside the submitted work. CB reports grants from Roche; and personal fees from Servier, Pierre Fabre, and Merck Sharpe and Dohme, outside the submitted work. All other authors declare no competing interests., (Copyright © 2021 Elsevier Ltd. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF
21. Quality of life and cost of strategies of two chemotherapy lines in metastatic colorectal cancer: results of the FFCD 2000-05 trial.
- Author
-
Lacas B, Bouché O, Etienne PL, Gasmi M, Texereau P, Gargot D, Lombard-Bohas C, Azzedine A, Denis B, Geoffroy P, Auby D, Michel P, Pignon JP, Lepage C, Ducreux M, and Borget I
- Subjects
- Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols economics, Camptothecin administration & dosage, Camptothecin analogs & derivatives, Camptothecin economics, Colorectal Neoplasms economics, Colorectal Neoplasms pathology, Drug Costs, Female, Fluorouracil administration & dosage, Fluorouracil economics, France, Health Status, Humans, Leucovorin administration & dosage, Leucovorin economics, Male, Middle Aged, Neoplasm Metastasis, Organoplatinum Compounds administration & dosage, Organoplatinum Compounds economics, Prospective Studies, Surveys and Questionnaires, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Colorectal Neoplasms drug therapy, Quality of Life
- Abstract
Objectives : This study compared the cost and quality of life (QoL) of 407 advanced colorectal cancer patients, randomly assigned to receive LV5FU2 followed by FOLFOX6 (sequential strategy) or FOLFOX6 followed by FOLFIRI (combination strategy). Methods : Costs were compared from the French health insurance perspective, until the end of the second line of treatment. Consumed resources, collected during the trial, included medicines, hospitalizations, examinations, and transportation. Valuations were made using 2009 and 2016 tariffs. QoL was assessed using the QLQ-C30 questionnaire and clinically significant variations were searched. Results : In 2009, the mean cost per patient was significantly lower for the sequential strategy compared to the combination strategy (18,061€ and 23,119€, p = 0.001). In 2016, the difference was no longer significant (16,876€ and 18,090€, p = 0.41) because oxaliplatin and irinotecan became generics. The QoL analysis (292 patients) showed that there was significantly less improvement of global health status in the sequential strategy than in the combination strategy (29% and 42%; p = 0.02) during first-line therapy. No significant differences were observed for emotional functioning (p = 0.45) and physical functioning (p = 0.07) or during second-line therapy. Conclusion : The choice to treat patients with advanced colorectal cancer using one or the other strategy cannot be based on costs or QoL.
- Published
- 2019
- Full Text
- View/download PDF
22. Geriatric factors analyses from FFCD 2001-02 phase III study of first-line chemotherapy for elderly metastatic colorectal cancer patients.
- Author
-
Aparicio T, Gargot D, Teillet L, Maillard E, Genet D, Cretin J, Locher C, Bouché O, Breysacher G, Seitz JF, Gasmi M, Stefani L, Ramdani M, Lecomte T, Auby D, Faroux R, Bachet JB, Lepère C, Khemissa F, Sobhani I, Boulat O, Mitry E, and Jouve JL
- Subjects
- Aged, Aged, 80 and over, Camptothecin administration & dosage, Camptothecin analogs & derivatives, Colorectal Neoplasms mortality, Disease-Free Survival, Female, Fluorouracil administration & dosage, Geriatric Assessment, Humans, Irinotecan, Kaplan-Meier Estimate, Karnofsky Performance Status, Male, Neoplasm Metastasis, Prospective Studies, Quality of Life, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Colorectal Neoplasms drug therapy
- Abstract
Aim: Several predictors of metastatic colorectal cancer (mCRC) outcomes have been described. Specific geriatric characteristics could be of interest to determine prognosis., Method: Elderly patients (75+) with previously untreated mCRC were randomly assigned to receive infusional 5-fluorouracil-based chemotherapy, either alone (FU) or in combination with irinotecan (IRI). Geriatric evaluations were included as an optional procedure. The predictive value of geriatric parameters was determined for the objective response rate (ORR), progression-free survival (PFS) and overall survival (OS)., Results: From June 2003 to May 2010, the FFCD 2001-02 randomised trial enrolled 282 patients. A baseline geriatric evaluation was done in 123 patients; 62 allocated to the FU arm and 61 to the IRI arm. The baseline Charlson index was ≤1 in 75%, Mini-Mental State Examination was ≤27/30 in 31%, Geriatric Depression Scale was >2 in 10% and Instrumental Activities of Daily Living (IADL) was impaired in 34% of the patients. Multivariate analyses revealed that no geriatric parameter was predictive for ORR or PFS. Normal IADL was independently associated with better OS. The benefit of doublet chemotherapy on PFS differed in subgroups of patients ≤80 years, with unresected primary tumour, leucocytes >11,000 mm
3 and carcinoembryonic antigen >2N. There was a trend towards better OS in patients with normal IADL., Conclusion: The autonomy score was an independent predictor for OS. A trend toward a better efficacy of doublet chemotherapy in some subgroups of patients was reported and should be further explored., (Copyright © 2016 Elsevier Ltd. All rights reserved.)- Published
- 2017
- Full Text
- View/download PDF
23. Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.
- Author
-
Thaler J, Greil R, Gaenzer J, Eisterer W, Tschmelitsch J, Samonigg H, Zabernigg A, Schmid F, Steger G, Steinacher R, Andel J, Lang A, Függer R, Hofbauer F, Woell E, Geissler D, Lenauer A, Prager M, Van Laethem JL, Van Cutsem E, D'Haens G, Demolin G, Kerger J, Deboever G, Ghillebert G, Polus M, Van Cutsem E, RezaieKalantari H, Delaunoit T, Goeminne JC, Peeters M, Vergauwe P, Houbiers G, Humblet Y, Janssens J, Schrijvers D, Vanderstraeten E, Van Laethem JL, Vermorken J, Van Daele D, Ferrante M, Forget F, Hendlisz A, Yilmaz M, Nielsen SE, Vestermark L, Larsen J, Ychou M, Zawadi A, Zawadi MA, Bouche O, Mineur L, Bennouna-Louridi J, Dourthe LM, Ychou M, Boucher E, Taieb J, Pezet D, Desseigne F, Ducreux M, Texereau P, Miglianico L, Rougier P, Fratte S, Levache CB, Merrouche Y, Ellis S, Locher C, Ramee JF, Garnier C, Viret F, Chauffert B, Cojean-Zelek I, Michel P, Lecaille C, Borel C, Seitz JF, Smith D, Lombard-Bohas C, Andre T, Gornet JM, Fein F, Coulon-Sfairi MA, Kaminsky MC, Lagasse JP, Luet D, Etienne PL, Gasmi M, Vanoli A, Nguyen S, Aparicio T, Perrier H, Stremsdoerfer N, Laplaige P, Arsene D, Auby D, Bedenne L, Coriat R, Denis B, Geoffroy P, Piot G, Becouarn Y, Bordes G, Deplanque G, Dupuis O, Fruge F, Guimbaud R, Lecomte T, Lledo G, Sobhani I, Asnacios A, Azzedine A, Desauw C, Galais MP, Gargot D, Lam YH, Abakar-Mahamat A, Berdah JF, Catteau S, Clavero-Fabri MC, Codoul JF, Legoux JL, Goldfain D, Guichard P, Verge DP, Provencal J, Vedrenne B, Brezault-Bonnet C, Cleau D, Desir JP, Fallik D, Garcia B, Gaspard MH, Genet D, Hartwig J, Krummel Y, MatysiakBudnik T, Palascak-Juif V, Randrianarivelo H, Rinaldi Y, Aleba A, Darut-Jouve A, de Gramont A, Hamon H, Wendehenne F, Matzdorff A, Stahl MK, Schepp W, Burk M, Mueller L, Folprecht G, Geissler M, Mantovani-Loeffler L, Hoehler T, Asperger W, Kroening H, von Weikersthal LF, Fuxius S, Groschek M, Meiler J, Trarbach T, Rauh J, Ziegenhagen N, Kretzschmar A, Graeven U, Nusch A, von Wichert G, Hofheinz RD, Kleber G, Schmidt KH, Vehling-Kaiser U, Baum C, Schuette J, Haag GM, Holtkamp W, Potenberg J, Reiber T, Schliesser G, Schmoll HJ, Schneider-Kappus W, Abenhardt W, Denzlinger C, Henning J, Marxsen B, GuenterDerigs H, Lambertz H, Becker-Boost I, Caca K, Constantin C, Decker T, Eschenburg H, Gabius S, Hebart H, Hoffmeister A, Horst HA, Kremers S, Leithaeuser M, Mueller S, Wagner S, Daum S, Schlegel F, Stauch M, Heinemann V, Labianca R, Colucci G, Amadori D, Mini E, Falcone A, Boni C, Maiello E, Latini L, Zaniboni A, Amadori D, Aprile G, Barni S, Mattioli R, Martoni A, Passalacqua R, Nicolini M, Pasquini E, Rabbi C, Aitini E, Ravaioli A, Barone C, Biasco G, Tamberi S, Gambi A, Verusio C, Marzola M, Lelli G, Boni C, Cascinu S, Bidoli P, Vaghi M, Cruciani G, Di Costanzo F, Sobrero A, Mini E, Petrioli R, Aglietta M, Alabiso O, Capuzzo F, Falcone A, Corsi DC, Labianca R, Salvagni S, Chiara S, Ferraù F, Giuliani F, Lonardi S, Gebbia N, Mantovani G, Sanches E, Sanches E, Mellidez JC, Santos P, Freire J, Sarmento C, Costa L, Pinto AM, Barroso S, Santo JE, Guedes F, Monteiro A, Sa A, Furtado I, Tabernero J, Salazar R, Aguilar EA, Herrero FR, Tabernero J, Valera JS, ValladaresAyerbes M, FeliuBatlle J, Gil S, Garcia-Giron C, Vivanco GL, Salvia AS, Orduña VA, Garcia RV, Gallego J, Sureda BM, Remon J, Safont Aguilera MJ, CireraNogueras L, Merino B, Castro CG, de Prado PM, PijaumePericay C, ConstenlaFigueiras M, Jordan I, GomeReina MJ, Garcia AL, Garcia-Ramos AA, Cervantes A, Martos CF, MarcuelloGaspar E, Montero IC, Emperador PE, Carbonero AL, Castillo MG, Garcia TG, Lopez JG, Flores EG, GuillotMorales M, LlanosMuñoz M, Martín AL, Maurel J, Camara JC, Garcia RD, Salgado M, HernandezBusquier I, Ruiz TC, LacastaMuñoa A, Aliguer M, Ortiz de Taranco AV, Ureña MM, Gaspa FL, Ponce JJ, Roig CB, Jimenez PV, GalanBrotons A, AlbiolRodriguez S, Martinez JA, Ruiz LC, CentellesRuiz M, Bridgewater J, Glynne-Jones R, Tahir S, Hickish T, Cassidy J, and Samuel L
- Published
- 2015
- Full Text
- View/download PDF
24. Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patients.
- Author
-
Aparicio T, Jouve JL, Teillet L, Gargot D, Subtil F, Le Brun-Ly V, Cretin J, Locher C, Bouché O, Breysacher G, Charneau J, Seitz JF, Gasmi M, Stefani L, Ramdani M, Lecomte T, and Mitry E
- Subjects
- Activities of Daily Living, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols adverse effects, Camptothecin administration & dosage, Camptothecin adverse effects, Camptothecin analogs & derivatives, Cognition Disorders chemically induced, Colorectal Neoplasms pathology, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Fluorouracil administration & dosage, Fluorouracil adverse effects, Humans, Irinotecan, Logistic Models, Male, Multivariate Analysis, Neoplasm Metastasis, Prospective Studies, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Colorectal Neoplasms drug therapy, Geriatric Assessment statistics & numerical data, Health Services for the Aged statistics & numerical data
- Abstract
Purpose: Elderly patients form a heterogeneous population. Evaluation of geriatric factors may help evaluate a patient's health status to better adapt treatment., Patients and Methods: Elderly patients with previously untreated metastatic colorectal cancer (mCRC) were randomly assigned to receive fluorouracil (FU) -based chemotherapy either alone or in combination with irinotecan (IRI) in the Fédération Francophone de Cancérologie Digestive (FFCD) 2001-02 study. Sites participating in the geriatric substudy completed geriatric screening tools to perform prognostic factor analyses for treatment safety during the first 4 months after treatment initiation., Results: The geriatric score was calculated in 123 patients (44%). Median age was 80 years (range, 75 to 91 years). The Charlson comorbidity index was ≤ 1 in 75%, Mini-Mental State Examination (MMSE) score was ≤ 27/30 in 31%, and Instrumental Activities of Daily Living (IADL) showed impairment in 34% of the patients. Seventy-one patients (58%) had grade 3 to 4 toxicity, 41 (33%) had a dose-intensity reduction of more than 33%, and 54 (44%) had at least one unexpected hospitalization during the first 4 months after starting treatment. In multivariate analysis, significant predictive factors for grade 3-4 toxicity were IRI arm (odds ratio [OR], 5.03), MMSE ≤ 27/30 (OR, 3.84), and impaired IADL (OR, 4.67); for dose-intensity reduction of > 33%, the significant predictive factors were alkaline phosphates > 2 × upper limit of normal (OR, 4.16) and IRI arm (OR, 6.85); and for unexpected hospitalization, significant predictive factors were MMSE ≤ 27/30 (OR, 4.56) and Geriatric Depression Scale ≤ 2 (OR, 5.52)., Conclusion: Geriatric factors (MMSE and IADL) are predictive of severe toxicity or unexpected hospitalization (MMSE) in a randomized prospective phase III study in mCRC. These results suggest that cognitive function and autonomy impairment should be taken into account when choosing a regimen for chemotherapy.
- Published
- 2013
- Full Text
- View/download PDF
25. Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study.
- Author
-
Barbare JC, Bouché O, Bonnetain F, Dahan L, Lombard-Bohas C, Faroux R, Raoul JL, Cattan S, Lemoine A, Blanc JF, Bronowicki JP, Zarski JP, Cazorla S, Gargot D, Thevenot T, Diaz E, Bastie A, Aparicio T, and Bedenne L
- Subjects
- Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Hormonal adverse effects, Double-Blind Method, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Octreotide adverse effects, Quality of Life, Survival Analysis, Treatment Outcome, Antineoplastic Agents, Hormonal therapeutic use, Carcinoma, Hepatocellular drug therapy, Liver Neoplasms drug therapy, Octreotide therapeutic use
- Abstract
Background: A previous study reported a significant survival benefit for octreotide compared with no treatment in patients with advanced hepatocellular carcinoma (HCC). This was investigated further in this multicentre study., Patients and Methods: Two hundred and seventy two patients with HCC who were ineligible for curative treatments or had relapsed following potentially curative therapies were randomised to receive long-acting octreotide, 30 mg as an intramuscular injection once every 4 weeks for up to 2 years, or placebo., Results: At the time of the final analysis, median overall survival (OS) was 6.53 months (95% confidence interval [CI], 4.8-8.3) for octreotide versus 7.03 months (95% CI, 5.43-8.53) for placebo (p=0.34). Progression-free survival (p=0.26) also did not differ significantly between the two treatment groups. No objective responses were achieved in the octreotide group but 33% of patients achieved disease stabilisation for a mean time of 5.5 months (95% CI, 1.1-9.9). The median time until definitive global health score deterioration (according to QLQ-C30) was 2.3 months (95% CI, 1.4-3.7) in the octreotide and 4 months (95% CI, 2.2-5.7) in the placebo group (p=0.09). There were four objective responses in the placebo group. Octreotide was well tolerated; seven patients reported severe adverse events possibly related to octreotide and there were no cases of haematoma or cholecystitis., Conclusions: In patients with advanced HCC, octreotide has a favourable safety profile but does not improve OS and could have a negative impact on quality of life.
- Published
- 2009
- Full Text
- View/download PDF
26. [Esophagitis associated with the use of alendronate].
- Author
-
Larzillière I, Gargot D, Zleik T, and Ramain JP
- Subjects
- Aged, Aged, 80 and over, Esophagitis diagnosis, Esophagoscopy, Female, Humans, Alendronate adverse effects, Esophagitis chemically induced
- Published
- 1999
27. [Microscopic colitis and Ticlid].
- Author
-
Larzillière I, Gargot D, Zleik T, and Ramain JP
- Subjects
- Humans, Male, Middle Aged, Colitis chemically induced, Platelet Aggregation Inhibitors adverse effects, Ticlopidine adverse effects
- Published
- 1999
28. Nonsteroidal anti-inflammatory drug-induced colonic strictures: two cases and literature review.
- Author
-
Gargot D, Chaussade S, d'Alteroche L, Desbazeille F, Grandjouan S, Louvel A, Douvin J, Causse X, Festin D, and Chapuis Y
- Subjects
- Aged, Aged, 80 and over, Anti-Inflammatory Agents, Non-Steroidal administration & dosage, Colonic Diseases epidemiology, Colonic Diseases pathology, Colonoscopy, Constriction, Pathologic chemically induced, Constriction, Pathologic epidemiology, Constriction, Pathologic pathology, Delayed-Action Preparations, Diclofenac administration & dosage, Drug Administration Schedule, Female, Humans, Male, Osteoarthritis drug therapy, Phenylbutazone administration & dosage, Spondylitis, Ankylosing drug therapy, Anti-Inflammatory Agents, Non-Steroidal adverse effects, Colonic Diseases chemically induced, Diclofenac adverse effects, Phenylbutazone adverse effects
- Abstract
We report two patients with large bowel submucosal diaphragm disease associated with nonsteroidal anti-inflammatory drugs (slow release form of diclofenac and phenylbutazone) who were admitted in 1990 and 1991 because of iron deficiency. At colonoscopy, the lumen of the ascending colon was divided into compartments by multiple thin circumferential mucosal membranes. Barium enema showed two short strictures in one patient. Right hemicolectomy was carried out on one patient. The other patient was simply advised to discontinue taking diclofenac and remains well. Such lesions are rare (10 cases have been reported) and resemble those previously described in the small bowel.
- Published
- 1995
29. [Liver steatosis. I: Macrovesicular steatosis].
- Author
-
Causse X, Gargot D, and Michenet P
- Subjects
- Diabetes Mellitus, Type 1 complications, Fatty Liver etiology, Fatty Liver pathology, Fatty Liver, Alcoholic pathology, Humans, Nutrition Disorders complications, Obesity complications, Fatty Liver physiopathology, Fatty Liver, Alcoholic physiopathology
- Published
- 1995
30. Association of hepatic vein obstruction and coeliac disease in North African subjects.
- Author
-
Marteau P, Cadranel JF, Messing B, Gargot D, Valla D, and Rambaud JC
- Subjects
- Adolescent, Adult, Africa, Northern, Celiac Disease diet therapy, Diet, Female, Glutens administration & dosage, Humans, Male, Budd-Chiari Syndrome complications, Celiac Disease complications
- Abstract
This study describes three adults with coeliac disease and hepatic vein obstruction, an association which has not been reported so far. Similarities were found with the cases of five children with Budd-Chiari syndrome and intestinal villous atrophy recently reported in the literature. All subjects had North African origin. Coeliac disease and Budd-Chiari syndrome are uncommon conditions, and it is postulated that this is probably not a chance association, although no link between these diseases and the ethnic origin of the subjects could be elucidated.
- Published
- 1994
- Full Text
- View/download PDF
31. [Endoscopic ligation of esophageal varices: feasibility in emergency].
- Author
-
Legoux JL, Festin D, Degand P, Gargot D, and Causse X
- Subjects
- Adult, Emergency Medicine, Esophageal and Gastric Varices complications, Humans, Ligation methods, Male, Middle Aged, Endoscopy, Gastrointestinal methods, Esophageal and Gastric Varices surgery, Gastrointestinal Hemorrhage etiology, Liver Cirrhosis, Alcoholic complications
- Published
- 1994
32. [Black esophagus: a new case associated with hypoxic hepatitis].
- Author
-
Gargot D, Causse X, Sapey T, Samuel D, Michenet P, Nguyen LD, Festin D, and Legoux JL
- Subjects
- Humans, Male, Middle Aged, Necrosis, Cardiomyopathy, Dilated complications, Esophageal Diseases etiology, Esophagus pathology, Hepatitis complications, Hypoxia complications
- Published
- 1994
33. Grand mal seizures as a complication of treatment with pefloxacin in patients with cirrhosis. A report of three cases.
- Author
-
Chapuis L, Cadranel JF, Nordmann P, Hagege H, Gargot D, Bernard B, Buffet C, Valla D, and Opolon P
- Subjects
- Child, Female, Humans, Liver Cirrhosis complications, Middle Aged, Pefloxacin administration & dosage, Epilepsy, Tonic-Clonic chemically induced, Liver Cirrhosis drug therapy, Pefloxacin adverse effects
- Abstract
In this paper, three cases of grand mal seizures are reported as a complication of pefloxacin at usual doses (400 mg twice a day) in patients with cirrhosis. Grand mal seizures occurred from 12 h to 8 days after the onset of pefloxacin treatment. In 1 case, seizures recurred after inadvertent rechallenge with the drug. Elevated pefloxacin serum levels were demonstrated in 2 cases. Brain computed tomography in all 3 cases and cerebrospinal fluid examination showed normal results. No etiology other than pefloxacin overdose was found. After pefloxacin withdrawal, no recurrence of seizures were observed. Therefore, when pefloxacin treatment is indicated for cirrhotic patients, a reduced dosage and/or careful monitoring of pefloxacin serum levels should be recommended.
- Published
- 1993
- Full Text
- View/download PDF
34. [Repercussions and undesirable effects of non-steroidal anti-inflammatory agents on the intestine. 1: Experimental data and pathophysiological effects].
- Author
-
Gargot D and Chaussade S
- Subjects
- Animals, Anti-Inflammatory Agents, Non-Steroidal administration & dosage, Anti-Inflammatory Agents, Non-Steroidal adverse effects, Cell Membrane Permeability drug effects, Dogs, Humans, Inflammation chemically induced, Intestines drug effects, Rats, Anti-Inflammatory Agents, Non-Steroidal pharmacology, Gastrointestinal Motility drug effects, Intestinal Absorption drug effects, Intestinal Diseases chemically induced, Ulcer chemically induced
- Published
- 1993
35. [Lymphocytic colitis, followed by collagenous colitis, associated with mycosis fungoides-type T-cell lymphoma].
- Author
-
Ouyahya F, Michenet P, Gargot D, Breteau N, Buzacoux J, and Legoux JL
- Subjects
- Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Colitis pathology, Collagen Diseases pathology, Colonoscopy, Combined Modality Therapy, Diarrhea etiology, Fatal Outcome, Humans, Lymphoma, T-Cell pathology, Male, Mycosis Fungoides therapy, Skin Neoplasms therapy, Colitis complications, Collagen Diseases complications, Lymphocytes, Lymphoma, T-Cell etiology, Mycosis Fungoides complications, Skin Neoplasms complications
- Published
- 1993
36. [Consequences and undesirable effects of non steroidal anti-inflammatory agents on the intestine. 2: Effects of NSAID on the small intestine and the colon].
- Author
-
Gargot D and Chaussade S
- Subjects
- Colitis chemically induced, Collagen Diseases chemically induced, Humans, Rectal Diseases chemically induced, Ulcer chemically induced, Anti-Inflammatory Agents, Non-Steroidal adverse effects, Colonic Diseases chemically induced, Ileal Diseases chemically induced, Intestinal Perforation chemically induced, Jejunal Diseases chemically induced
- Published
- 1993
37. Spontaneous dialytic ultrafiltration with intraperitoneal reinfusion of the concentrate versus large paracentesis in cirrhotic patients with intractable ascites: a randomized study.
- Author
-
Cadranel JF, Gargot D, Grippon P, Lunel F, Bernard B, Valla D, and Opolon P
- Subjects
- Ascites complications, Ascitic Fluid, Dialysis, Humans, Liver Cirrhosis complications, Punctures, Ascites therapy, Drainage, Liver Cirrhosis therapy, Ultrafiltration
- Abstract
Dialytic ultrafiltration of ascites through a hemofilter associated with peritoneal reinfusion (DUF) of the concentrate has been proposed for the treatment of refractory ascites. In five cirrhotic patients, 18 ascites evacuation procedures were randomized either to DUF (n = 8) or to large paracenteses (LP) (n = 10). The effects of these two methods on hemodynamic and renal function were assessed. After DUF, the protein concentration in ascites increased transiently from 28 +/- 7 g/l to 64.8 +/- 8 g/l (p less than 0.04); urinary output increased from day 1 to day 4 (1000 +/- 100) VS 1430 +/- 140 ml/24h; p less than 0.02). After LP, ascitic protein concentration and urinary output were unchanged. No side effects were observed with the two methods. The mean amount of albumin infused was 20 +/- 15 g after DUF and 15 +/- 5 after LP (ns).
- Published
- 1992
38. Spontaneous dialytic ultrafiltration with intraperitoneal reinfusion of the concentrate in 15 cirrhotic patients with intractable ascites.
- Author
-
Cadranel JF, Grippon P, Gargot D, Lunel F, Bernard B, Valla D, and Opolon P
- Subjects
- Ascites metabolism, Evaluation Studies as Topic, Humans, Infusions, Parenteral, Liver Cirrhosis metabolism, Remission Induction, Sodium urine, Time Factors, Ultrafiltration instrumentation, Ascites therapy, Liver Cirrhosis therapy, Peritoneal Dialysis methods, Ultrafiltration methods
- Abstract
The clinical efficacy and tolerance of dialytic ultrafiltration of ascites through a hemofilter (DUF) with peritoneal reinfusion of the concentrate was evaluated in 15 cirrhotic patients with intractable ascites. All together, 51 DUF procedures were carried out. An average of 8.6 was ultrafiltered during 12 h with no significant change in blood pressure, hemoglobin, coagulation parameters or plasma creatinine. A significant increase in ascitic protein concentration was observed immediately after the procedure and a slight but significant increase in 24 h urinary output. A controlled evaluation of DUF compared to large paracenteses seems to be justified by these preliminary results.
- Published
- 1992
39. [Is there an association between arteriovenous malformation of the colon (angiodysplasia) and aortic stenosis?].
- Author
-
Gargot D, Cadranel JF, Moussali J, Benhamou Y, Valla D, and Opolon P
- Subjects
- Aged, Angiodysplasia physiopathology, Aortic Valve Stenosis epidemiology, Aortic Valve Stenosis surgery, Colonic Diseases physiopathology, Gastrointestinal Hemorrhage epidemiology, Heart Valve Prosthesis, Humans, Middle Aged, Prevalence, Recurrence, Angiodysplasia complications, Aortic Valve Stenosis complications, Colonic Diseases complications, Gastrointestinal Hemorrhage etiology
- Published
- 1992
40. [Cytolytic hepatitis and wild Germander: a new case with reintroduction].
- Author
-
Legoux JL, Maitre F, Labarrière D, Gargot D, Festin D, and Causse X
- Subjects
- Adult, Female, Humans, Liver Function Tests, Phytotherapy, Chemical and Drug Induced Liver Injury etiology, Plant Poisoning, Plants, Medicinal
- Published
- 1992
41. [Ogilvie's syndrome associated with treatment by loperamide and nifedipine].
- Author
-
Lelouch S, Cadranel JF, Moussalli J, Benhamou Y, Gerosa Y, Gargot D, and Opolon P
- Subjects
- Aged, Humans, Male, Syndrome, Colonic Pseudo-Obstruction chemically induced, Loperamide adverse effects, Nifedipine adverse effects
- Published
- 1991
42. [Granulomatous hepatitis following intravesical BCG immunotherapy for cancer of the bladder].
- Author
-
Gargot D, Alexandre L, Sinico M, Salmeron S, Benoit G, and Buffet C
- Subjects
- Administration, Intravesical, BCG Vaccine administration & dosage, BCG Vaccine therapeutic use, Humans, Male, Middle Aged, BCG Vaccine adverse effects, Chemical and Drug Induced Liver Injury etiology, Urinary Bladder Neoplasms therapy
- Published
- 1991
43. [Moxisylyte-induced cytolytic hepatitis?].
- Author
-
Lévy-Bruhl A, Germanaud J, Gargot D, and Legoux JL
- Subjects
- Aged, Humans, Male, Moxisylyte therapeutic use, Prostatic Hyperplasia drug therapy, Chemical and Drug Induced Liver Injury etiology, Moxisylyte adverse effects
- Published
- 1991
44. [Spontaneous esophageal perforation: the value of various radiologic tests].
- Author
-
Cadranel JF, Gargot D, Grippon P, Luciani F, Zylberberg P, Saigot T, Bousquet O, and Opolon P
- Subjects
- Endoscopy, Humans, Tomography, X-Ray Computed, Esophageal Perforation diagnostic imaging
- Published
- 1990
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.